文献速递血管炎

美泊利珠单抗对嗜酸性肉芽肿性多血管炎患者AAV-PRO问卷的影响:一项欧洲多中心研究数据

Impact of mepolizumab on the AAV-PRO questionnaire in eosinophilic granulomatosis with polyangiitis: data from a European multicentre study.
PubMed 文献 · Rheumatology (Oxford) · 2025-01-01

该前瞻性国际多中心队列纳入70例活动性EGPA起始美泊利珠单抗治疗的患者,在基线及第7、14、30、90、180天评估PtGA和AAV-PRO。PtGA在7天内即显著下降,14天时除治疗副作用外所有AAV-PRO领域均显著改善,6个月时器官特异性症状、躯体功能和PtGA改善最大。

要点

  • 美泊利珠单抗治疗后PtGA在7天内即出现统计学显著下降。
  • 14天时除治疗副作用外所有AAV-PRO领域均显著改善。
  • 6个月时器官特异性症状(比值0.53)、躯体功能(比值0.57)和PtGA(比值0.58)改善最大。

核心结论

  • 美泊利珠单抗与EGPA患者健康相关生活质量的快速且显著改善相关。
  • 这些发现突显其超越疾病控制的早期和持续获益,并支持将AAV-PRO问卷整合入常规临床实践。

研究设计与样本

  • 前瞻性国际多中心队列研究,纳入70例起始美泊利珠单抗治疗的活动性EGPA患者。
  • 在基线及第7、14、30、90和180天评估PtGA和AAV-PRO评分,并探究AAV-PRO问卷应答的预测因素。

主要发现

  • 女性占54.3%,中位年龄56岁(48-65),63例(90%)为复发/难治性病程。
  • PtGA在7天内出现统计学显著下降。
  • 14天时除治疗副作用外所有AAV-PRO领域均显示统计学显著下降。
  • 6个月时改善最大的是器官特异性症状(比值0.53)、躯体功能(比值0.57)和PtGA(比值0.58)。
  • PtGA和较高疾病活动度在整个研究期间与AAV-PRO评分呈正相关;女性患者在系统性症状、治疗副作用、社会和情感影响及对未来的担忧方面报告更大负担;年龄、教育水平、损伤累积、美泊利珠单抗剂量和ANCA状态对AAV-PRO评分无影响。

临床怎么用

  • 作者认为这些发现支持将AAV-PRO问卷整合入常规临床实践。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To prospectively evaluate the impact and the rapidity of the effect of mepolizumab on the ANCA-associated vasculitis patient-reported outcomes (AAV-PRO) questionnaire and patient global assessment (PtGA) in an international, multicentre cohort of patients with eosinophilic granulomatosis with polyangiitis (EGPA). METHODS: Patients with active EGPA initiating treatment with mepolizumab were included. PtGA and the AAV-PRO score were assessed at baseline and after 7, 14, 30, 90 and 180 days. Predictors of response of the AAV-PRO questionnaire were investigated. RESULTS: Seventy patients were included: female 54.3%, median age 56 years (48-65), 63 (90%) with a relapsing/refractory course. PtGA showed a statistically significant decrease within 7 days. At 14 days, all the AAV-PRO domains, except treatment side effects, showed a statistically significant decline. The improvement at 6 months was greatest in organ-specific symptoms (ratio 0.53), physical function (ratio 0.57) and PtGA (ratio 0.58). PtGA and higher disease activity positively correlated with the AAV-PRO scores throughout the study. Female patients reported a greater burden in terms of systemic symptoms, treatment side effects, social and emotional impact and concerns about the future. Conversely, age, educational level, damage accrual, mepolizumab dose and ANCA status had no effect on the AAV-PRO scores. CONCLUSIONS: Mepolizumab was associated with a quick and remarkable improvement of health-related quality of life in patients with EGPA. These findings highlight its early and sustained benefits beyond disease control and support the integration of the AAV-PRO questionnaire into routine clinical practice.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Delvino P, Quartuccio L, Robson JC, et al. Impact of mepolizumab on the AAV-PRO questionnaire in eosinophilic granulomatosis with polyangiitis: data from a European multicentre study. Rheumatology (Oxford). 2025. PMID: 40286311. doi:10.1093/rheumatology/keaf232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。